dc.creatorLópez León, Micaela
dc.creatorOuteiro, Tiago F.
dc.creatorGoya, Rodolfo Gustavo
dc.date2017
dc.date2021-09-16T16:20:33Z
dc.date.accessioned2023-07-15T03:08:46Z
dc.date.available2023-07-15T03:08:46Z
dc.identifierhttp://sedici.unlp.edu.ar/handle/10915/124991
dc.identifierissn:1872-9649
dc.identifierissn:1568-1637
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/7464612
dc.descriptionAging is associated with a progressive increase in the incidence of neurodegenerative diseases, with Alzheimer's (AD) and Parkinson's (PD) disease being the most conspicuous examples. Within this context, the absence of efficacious therapies for most age-related brain pathologies has increased the interest in regenerative medicine. In particular, cell reprogramming technologies have ushered in the era of personalized therapies that not only show a significant potential for the treatment of neurodegenerative diseases but also promise to make biological rejuvenation feasible. We will first review recent evidence supporting the emerging view that aging is a reversible epigenetic phenomenon. Next, we will describe novel reprogramming approaches that overcome some of the intrinsic limitations of conventional induced-pluripotent-stem-cell technology. One of the alternative approaches, lineage reprogramming, consists of the direct conversion of one adult cell type into another by transgenic expression of multiple lineage-specific transcription factors (TF). Another strategy, termed pluripotency factor-mediated direct reprogramming, uses universal TF to generate epigenetically unstable intermediates able to differentiate into somatic cell types in response to specific differentiation factors. In the third part we will review studies showing the potential relevance of the above approaches for the treatment of AD and PD.
dc.descriptionInstituto de Investigaciones Bioquímicas de La Plata
dc.formatapplication/pdf
dc.format168-181
dc.languageen
dc.rightshttp://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rightsCreative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0)
dc.subjectCiencias Médicas
dc.subjectBrain aging
dc.subjectCell reprogramming
dc.subjectRejuvenation
dc.subjectDirect reprogramming
dc.subjectTransdifferentiation
dc.subjectParkinsońs disease
dc.subjectAlzheimer’s disease
dc.titleCell reprogramming: Therapeutic potential and the promise of rejuvenation for the aging brain
dc.typeArticulo
dc.typePreprint


Este ítem pertenece a la siguiente institución